Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center
Dec 08,2023
Medicilon Assists Longsee Biomedical's live bacteria preparation LF01 capsules approved for clinical use
On November 20, LF01, an innovative anti-tumor drug independently developed by Longsee Biomedical Co. Ltd. (Longsee Biomedical), received the NMPA drug clinical trial approval notice. Medicilon provided non-clinical safety evaluation and filing application services for the research and development of LF01.
See More
Medicilon Assists Longsee Biomedical's live bacteria preparation LF01 capsules approved for clinical use
Dec 08,2023
Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation site inhibitor YY201 successfully completed dual submissions in China and US
Medicilon provided YY201 with pharmaceutical research services (including APIs and preparations), preclinical research services (including efficacy, pharmacokinetics, safety evaluation), and IND application services, which helped YY201 successfully complete dual submissions in China and US.
See More
Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation site inhibitor YY201 successfully completed dual submissions in China and US
Nov 22,2023
Medicilon Assists Huaota's CD73-targeting ADC approved for clinical use in US
Recently, Shanghai Huaota Biopharmaceutical Co., Ltd. (Huaota) received a notification from the US FDA, agreeing that the third-generation antibody drug conjugate (ADC) project HB0052 developed by the company targeting the CD73 antigen will enter clinical trials. This is the first antibody conjugate drug project approved by Huaota Biotech to enter clinical trials by the FDA.
See More
Medicilon Assists Huaota's CD73-targeting ADC approved for clinical use in US
Nov 13,2023
Medicilon Assists Gluetacs Therapeutics' second molecular rubber pipeline line GT929 achieves dual filing and batching in China and US
​On October 27, Gluetacs Therapeutics' second Class 1 new drug, GT929 capsule, in its molecular glue degrader pipeline, was approved by the U.S. Food and Drug Administration (FDA) to enter clinical trials for the treatment of malignant hematological tumors.
See More
Medicilon Assists Gluetacs Therapeutics' second molecular rubber pipeline line GT929 achieves dual filing and batching in China and US
Nov 01,2023
Medicilon assists LX-132 capsule, a new-targeted anti-tumor drug developed by Salustier Biosciences, successfully obtained clinical approval for a Class I new drug
Recently, LX-132 capsules, a new generation of irreversible kinase inhibitor independently developed by Salustier Biosciences, received a drug clinical trial approval notice from the NMPA. Medicilon has provided a full set of preclinical research services for the research and development of LX-132.
See More
Medicilon assists LX-132 capsule, a new-targeted anti-tumor drug developed by Salustier Biosciences, successfully obtained clinical approval for a Class I new drug
Aug 24,2023
Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the Treatment of Patients with Brain Glioblastoma Carrying BRAF V600 Mutation
ABM Therapeutics announced that its self-developed small molecule BRAF inhibitor ABM-1310 has obtained orphan drug qualification from the US FDA for the treatment of BRAF V600 mutant brain glioblastoma (GBM). Medicilon provided drug discovery services in a flexible cooperation mode.
See More
Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the Treatment of Patients with Brain Glioblastoma Carrying BRAF V600 Mutation
Aug 04,2023
Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation inhibitor YY201 has been approved for clinical trials
Medicilon, as a partner of Yuyao Biotech, provided YY201 with pharmaceutical research services (including raw materials and preparations), preclinical research services (including drug efficacy, pharmacokinetics, safety evaluation) and IND declaration services, helping YY201 successfully pass IND approval and enter the clinical trial stage.
See More
Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation inhibitor YY201 has been approved for clinical trials
Jul 27,2023
Medicilon Assisted - The IND application of BIOT-001, the first self-developed new drug of Biotime Biotechnology, was approved by the FDA
The IND application for the BIOT-001 project targeting the S1P1 target declared by Biotime Biotechnology obtained the US FDA's clinical implied license. Medicilon provided preclinical R&D services from target to IND declaration for the R&D of BIOT-001, and made every effort to complete the project with high quality and efficiency.
See More
Medicilon Assisted - The IND application of BIOT-001, the first self-developed new drug of Biotime Biotechnology, was approved by the FDA
Jul 27,2023
Medicilon Assist - The IND application for the first new drug NB002 of Neologics Bioscience was approved by the FDA for clinical application
Recently, Neologics Bioscience announced that its research and development pipeline NB002 for the treatment of solid tumors has successfully passed the review of the US FDA and agreed to conduct phase I clinical trials. Medicilon provided preclinical research services such as safety evaluation and pharmacokinetics.
See More
Medicilon Assist - The IND application for the first new drug NB002 of Neologics Bioscience was approved by the FDA for clinical application
Jun 26,2023
Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I
MindRank's GLP-1RA small molecule oral drug has been successfully administered to the first subject in clinical phase I. Medicilon as a strategic partner of MindRank, provided MDR-001 with API process development and preparation R&D services to help speed up its research and development.
See More
Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I